Recently added

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc

Takekuma, Munetaka; Nishio, Shin; Yamaguchi, Satoshi; Yunokawa, Mayu; Nishio, Hiroshi; Nishino, Koji; Villacampa Javierre, Guillermo; OAKNIN, ANA (Korean Society of Gynecologic Oncology, 2025-11)

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

Hernando, Jorge; BENAVENT VIÑUALES, MARTA; Capdevila Castillon, Jaume; Molina-Cerrillo, Javier; Garcia-Carbonero, Rocio; Teule, Alex (American Association for Cancer Research, 2025-11-15)

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Li, Weimin; Spira, Alexander; Sauder, Maxwell; Feldman, Jill; Bozorgmehr, Farastuk; Cho, Byoung Chul; FELIP, ENRIQUETA (Elsevier, 2025-10)

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Even, Caroline; Massarelli, Erminia; Laban, Simon; FAYETTE, Jérôme; Oliva Bernal, Marc; Harrington, Kevin; Brana, Irene (BMJ, 2025-09)

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients

Catani, Greta; Alcaraz Soler, Adriana; García, Ariadna I.; Elez, Elena; Salvà, Francesc; Saoudi Gonzalez, Nadia; Baraibar, Iosune; Ros, Javier; R Castells, Marta; Salva de Torres, Clara; Comas Navarro, Raquel; Ruiz Pace, Fiorella; Rezqallah Arón , María Alejandra; Dienstmann, Rodrigo; Tabernero, Josep (Elsevier, 2025-09)

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc ﻿

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914) ﻿

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial ﻿

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer ﻿

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients ﻿

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients